Targeting NMDA receptors with an antagonist is a promising therapeutic strategy for treating neurological disorders
- 3 August 2024
- journal article
- research article
- Published by Elsevier in Behavioural Brain Research
- Vol. 472, 115173
Abstract
No abstract availableKeywords
This publication has 117 references indexed in Scilit:
- MK-801 and cognitive functions: Investigating the behavioral effects of a non-competitive NMDA receptor antagonistPsychopharmacology, 2023
- Global Prevalence and Incidence of TinnitusJAMA Neurology, 2022
- Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary reviewPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2022
- Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double‐blind, placebo‐controlled trialNeuropsychopharmacology Reports, 2022
- Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV‐5500) in PTSD: A randomized, double‐blind, placebo‐controlled trialDepression and Anxiety, 2021
- Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndromeAnnals of Clinical and Translational Neurology, 2020
- NMDA receptor antagonists traxoprodil and lanicemine improve hippocampal-prefrontal coupling and reward-related networks in ratsPsychopharmacology, 2019
- Long‐term potentiation inhibition by low‐level N‐methyl‐D‐aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen‐activated protein kinaseHippocampus, 2007
- Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's diseaseJournal of Neural Transmission, 1992
- The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodentsNaunyn-Schmiedeberg's Archives of Pharmacology, 1990